FREMONT, Calif., April 16 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) today presented data on the discovery of several protein biomarkers that may be potential diagnostic markers in detection of early- stage ovarian cancer. These findings support one of three diagnostic programs that Ciphergen currently has under development for ovarian cancer. These findings were presented at the American Association for Cancer Research Annual Meeting in Los Angeles, Calif.
